-
-
Overview
-
Remsima®,the world first biosimilar mAb (approved in 2013 by EMA). The Agencys Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade®. The Shikari® Infliximab-Remsima® ELISA has been especially developed for the quantitative analysis of free infliximab in serum and plasma samples.
Please contact us at for specific academic pricing.
More Details
-
- Properties
- Applications
-
Overview